Cancer
-
Randomized Controlled Trial Comparative Study Clinical Trial
Comparison of intermittent ondansetron versus continuous infusion metoclopramide used with standard combination antiemetics in control of acute nausea induced by cisplatin chemotherapy.
Ondansetron is a serotonin antagonist that recently has been introduced as a preventive agent for chemotherapy-induced nausea and vomiting. The current study was performed to determine the degree of antiemetic control of ondansetron in combination with dexamethasone and lorazepam, and to compare this combination to the previously very effective regimen of lorazepam, dexamethasone, diphenhydramine, and continuous-infusion metoclopramide. ⋯ The ondansetron regimen was more effective and less toxic, but its cost was 20 times more than the metoclopramide regimen.
-
An increased incidence of cancer, especially hematopoietic in origin, has long been suspected but never established in patients with Gaucher disease. ⋯ The authors conclude that patients with Gaucher disease have a significantly increased risk of cancer, occurring in late adulthood. Of all the cancers, hematologic cancers are significantly more prevalent.